ATE290384T1 - Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen - Google Patents
Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungenInfo
- Publication number
- ATE290384T1 ATE290384T1 AT99964611T AT99964611T ATE290384T1 AT E290384 T1 ATE290384 T1 AT E290384T1 AT 99964611 T AT99964611 T AT 99964611T AT 99964611 T AT99964611 T AT 99964611T AT E290384 T1 ATE290384 T1 AT E290384T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- etherlysophospholipides
- inflammatory diseases
- chronic inflammatory
- etherlysophospholipids
- Prior art date
Links
- 208000037976 chronic inflammation Diseases 0.000 title 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 title 1
- 102100037611 Lysophospholipase Human genes 0.000 abstract 1
- 108010058864 Phospholipases A2 Proteins 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98124340 | 1998-12-21 | ||
| PCT/EP1999/010122 WO2000037088A1 (en) | 1998-12-21 | 1999-12-20 | Use of etherlysophospholipids as antiinflammatory agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE290384T1 true ATE290384T1 (de) | 2005-03-15 |
Family
ID=8233199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99964611T ATE290384T1 (de) | 1998-12-21 | 1999-12-20 | Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6583127B1 (de) |
| EP (1) | EP1140112B1 (de) |
| JP (1) | JP2002532553A (de) |
| AT (1) | ATE290384T1 (de) |
| CA (1) | CA2356736A1 (de) |
| DE (1) | DE69924146D1 (de) |
| WO (1) | WO2000037088A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6838452B2 (en) * | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| DK1343013T3 (da) * | 2002-03-07 | 2006-08-21 | Pasteur Institut | Fremgangsmåder til screening af forbindelser der modulerer apoptose, forbindelser der er identificeret ved fremgangsmåderne, og anvendelse af forbindelserne som terapeutiske midler |
| US8383605B2 (en) * | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
| PT1545553E (pt) * | 2002-07-30 | 2011-09-12 | Aeterna Zentaris Gmbh | Utilização de alquilfosfocolinas em combinação com medicamentos antitumorais |
| KR100673125B1 (ko) * | 2005-04-15 | 2007-01-22 | 주식회사 하이닉스반도체 | 포토 마스크 |
| EP1981488A1 (de) * | 2005-12-23 | 2008-10-22 | Jado Technologies GmbH | Mittel und verfahren für therapie und prophylaxe von allergischen erkrankungen |
| WO2008055996A1 (en) * | 2006-11-10 | 2008-05-15 | Alphaptose Gmbh | Oral dosage form comprising tri-substituted glycerol compounds |
| US8637688B2 (en) * | 2006-12-20 | 2014-01-28 | Julia Diederichs | Topical dosage form comprising tri-substituted glycerol compounds |
| EP2536414B1 (de) | 2010-02-18 | 2016-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren zur vorbeugung von krebsmetastasen |
| WO2011123691A1 (en) | 2010-03-31 | 2011-10-06 | Keryx Biopharmaceuticals, Inc. | Perifosine and capecitabine as a combined treatment for cancer |
| WO2014166941A1 (en) * | 2013-04-08 | 2014-10-16 | Academisch Medisch Centrum | Miltefosin or perifosin for use in the treatment of ibd |
| WO2020123409A1 (en) * | 2018-12-12 | 2020-06-18 | Buck Institute For Research On Aging | S3qels to protect against intestinal permeability |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3530767A1 (de) * | 1985-08-28 | 1987-03-12 | Max Planck Gesellschaft | Mittel gegen multiple sklerose |
| DE3918082A1 (de) * | 1989-06-02 | 1991-01-24 | Max Planck Gesellschaft | Mittel gegen autoimmunerkrankungen |
| US6172050B1 (en) * | 1992-07-11 | 2001-01-09 | Asta Medica Aktiengesellschaft | Phospholipid derivatives |
| EP0785773B1 (de) | 1994-10-14 | 2001-01-03 | The Liposome Company, Inc. | Etherlipid-liposomen und deren therapeutische verwendung |
| US5716959A (en) * | 1996-02-13 | 1998-02-10 | T. Ronald Theodore | Method of treating disease with piperazine zwitterion compounds |
| US5965159A (en) * | 1996-02-16 | 1999-10-12 | The Liposome Company, Inc. | Etherlipid-containing multiple lipid liposomes |
| US5942246A (en) | 1996-02-16 | 1999-08-24 | The Liposome Company, Inc. | Etherlipid containing multiple lipid liposomes |
-
1999
- 1999-12-20 CA CA002356736A patent/CA2356736A1/en not_active Abandoned
- 1999-12-20 AT AT99964611T patent/ATE290384T1/de not_active IP Right Cessation
- 1999-12-20 EP EP99964611A patent/EP1140112B1/de not_active Expired - Lifetime
- 1999-12-20 DE DE69924146T patent/DE69924146D1/de not_active Expired - Lifetime
- 1999-12-20 JP JP2000589199A patent/JP2002532553A/ja active Pending
- 1999-12-20 WO PCT/EP1999/010122 patent/WO2000037088A1/en not_active Ceased
- 1999-12-20 US US09/868,571 patent/US6583127B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1140112A1 (de) | 2001-10-10 |
| WO2000037088A1 (en) | 2000-06-29 |
| JP2002532553A (ja) | 2002-10-02 |
| CA2356736A1 (en) | 2000-06-29 |
| US6583127B1 (en) | 2003-06-24 |
| EP1140112B1 (de) | 2005-03-09 |
| DE69924146D1 (de) | 2005-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE461698T1 (de) | Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden | |
| EA200201247A1 (ru) | Соединения для лечения болезни альцгеймера | |
| NO20083956L (no) | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| DE69920757D1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
| ATE290384T1 (de) | Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen | |
| ATE323490T1 (de) | Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung | |
| ATE383160T1 (de) | Phosphinsäurederivate, inhibitoren von beta- sekretase zur behandlung von alzheimer-krankheit | |
| DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| NO20014241D0 (no) | C16-umettede FP-selektive prostaglandinanaloger | |
| ATE319473T1 (de) | Melagatran zur behandlung von entzündungen | |
| SE0002739D0 (sv) | New use | |
| DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| DE60124093D1 (de) | S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen. | |
| DE60330233D1 (de) | Arsentherapie zur behandlung von autoimmunerkrankungen | |
| ATE341323T1 (de) | Verwendung von darifenacin zur behandlung des harndrangs | |
| ATE486594T1 (de) | Methode zur behandlung von herzinsuffizienz | |
| DE69915849D1 (de) | Verwendung von gnrh analogen zur behandlung von schizophrenie | |
| DE69924385D1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
| ATE350034T1 (de) | Verwendung von epothilone zur behandlung hyperparathyreoidismus | |
| DE60305018D1 (de) | Citalopram zur behandlung von bluthochdruck | |
| DE60108775D1 (de) | Methode zur behandlung von schlaganfall |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |